ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0324

A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (OAKP) – Study 301
Abstract Number: 0325

Understanding the Burden of Cutaneous Lupus: A Subset Analysis from the 2022 World Lupus Federation Global Impact (WLFGI) Patient Survey
Abstract Number: 0326

Assessment of Depression in Ankylosing Spondylitis Using Center for Epidemiologic Studies Depression Scale
Abstract Number: 0327

Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre
Abstract Number: 0328

From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Abstract Number: 0329

Factors Associated with Suicidal Ideation Among Patients with Inflammatory Rheumatic Musculoskeletal Disease: A Case-Control Study
Abstract Number: 0330

Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement
Abstract Number: 0331

Assessment of Patient Adherence to “Sick Day Rules”: A Cross-sectional Study of Rheumatology Outpatients Prescribed Immunosuppressive Medications
Abstract Number: 0332

Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Abstract Number: 0333

Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Abstract Number: 0334

Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus
Abstract Number: 0335

Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool
Abstract Number: 0336

Core Signs Associated with the Subtypes of Cutaneous Lupus Erythematosus: Concept Elicitation Interviews with Dermatologists and Rheumatologists
Abstract Number: 0337

Impact of Photosensitivity on Quality of Life in Dermatomyositis
Abstract Number: 0338

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data from COVAD Patient-reported E-survey

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].